virtualitp conference

2021

PlateletDisorderSupportAssociation

The premier patient event,connecting the global ITP

community.

T H A N K Y O U T O O U R 2 0 2 1 N A T I O N A L I T P C O N F E R E N C E S P O N S O R S

PLATINUM SPONSOR GOLD SPONSORS SILVER SPONSORS

july 30 - august 1

Strongertogether.

GLOBAL  ITP AWARENESS WEEK

SPORT PURPLE FOR PLATELETS!

20% DISCOUNT in THE PLATELET STORE

Fr iday , September 24th i s the day that anyth ing purple goes .Get your purple on ! Don your purple a t t i re , ha i r , na i l s , hats , footwear and more ! Dress you pets , and deck your ha l ls w i th purple l ights ! Then ,  SHARE YOUR PICS and insp i re us  us ing # ITPaware .

From September 20-24th , jo in the g lobal movement and pa intsoc ia l media purple us ing #ITPaware and #global4 ITP !V is i t g lobal ITP .org

YOUR WALK, YOUR WAY! Pump I t Up For P la te lets ! i s a movement , a communi ty of pat ients , careg ivers , vo lunteersand par t ic ipants in the Un i ted States and Canada who bel ieve in a br ight future for immune thrombocytopen ia ( ITP) andother p la te let d isorders . This year ’s hybr id program o f fers more ways than ever for the ITP communi ty to come together ,fundra ise , and jo in the cause – in-person or v i r tual ly – f rom wherever you are !LEARN MORE & REGISTER TODAY a t ITPwalk .org

ITP AWARENESS MONTH

Shop our exc lus ive i tems in The P late let Store anyt imedur ing the month of September and enjoy 20% off yourpurchase! A l l proceeds benef i t PDSA.

SEPTEMBER IS

PUMP IT UP FOR PLATELETS! 2021

About thePlatelet Disorder Support Association

The Platelet Disorder Support Association (PDSA) is dedicated to enhancing the lives of people with immunethrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support.Patient-founded in 1998 to educate and empower those impacted by ITP and other rare platelet and bleedingdisorders, PDSA is now a powerful force serving and unifying the global community of patients, practitioners,caregivers, advocates and key disease stakeholders. PDSA is committed to building awareness, educating theglobal community, and providing critical connections and resources that empower patients to take charge oftheir disease and encourage practitioners to exercise patient-centered medical care.

PDSA receives no federal funding. It never has. Charitable gifts from our individual and corporate donors,membership contributions, and inspiring awareness and philanthropic events coordinated by committedvolunteers energize, uphold and preserve our mission.

PATIENT EDUCATION - PDSA is home to the most extensive patient-focused library of current disease,treatment and research information available online and in print.

PATIENT SUPPORT - Our patient-centered programs and services connect ITP patients and caregivers,build awareness, promote community, and empower ITP patients to take control of their disease.

AWARENESS & ADVOCACY - We are committed to ongoing awareness, advocacy and collaborations withother patient advocacy groups, researchers and government agencies to drive public policy, develop newtreatment options and fund research to find a cure.

PLATELET DISORDER RESEARCH - We support investigations that examine the pathogenesis andmanagement of primary ITP and present the most promising outlook to significantly improve diagnosis,therapies, and patient quality of life.

Peter Pruitt, ChairKaren Avrick

Kim Everett, Treasurer

Robert FeinerMelissa Hilsabeck

Linda McGuirl

Dale Paynter, Vice-ChairBeth Siegelbaum, Secretary

Derek Zimmerman

BOARD OF DIRECTORS:

PDSA Programs and Services

Caroline Kruse, President & CEOJeff Cooper, Website & Social Media Manager

Jennifer DiRaimo, Research Program ManagerBrenda Foster, Administrative Manager

Teri Howe, Director of Development & CommunicationsEmily Innes, Programs & Marketing Associate

Loni Kirsch, Administrative AssistantAlexandra Kruse, Research Coordinator

Susan Mason, Chief Financial OfficerNancy Potthast, Director of Marketing

Jody Shy, Director of Programs & EventsJoan Young, PDSA Founder

OFFICERS AND STAFF:

Donald Arnold, MDCM, MSc, FRCP(C)James Bussel, MD, Chair

Douglas Cines, MDNichola Cooper, MD

Terry Gernsheimer, MD

Andra H. James, MD, MPHCraig Kessler, MD

David Kuter, MD, DPhilMichele Lambert, MD, MSTR

Howard A. Liebman, MD

Robert McMillan, MD, EmeritusDiane Nugent, MDDrew Provan, MDJohn Semple, PhD

Michael Tarantino, MD

MEDICAL ADVISORS:

PDSA | 8751 Brecksville Rd. | Suite 150 | Cleveland, OH | 44141440-746-9003 | pdsa@pdsa.org | www.pdsa.org

So much can happen in a year. One year ago, we were beginning our first ever virtualconference, unsure of what the next few months would bring and how we could continueto combat the COVID-19 virus that had already done so much damage and continued todisrupt the lives of so many people around the world. We held out hope that our 2021 ITPPatient Conference could be an in-person event, but ultimately recognized it would not yetbe possible to safely bring the ITP community, PDSA staff, medical professionals, andindustry leaders together. As we gather once again on our unique virtual platform forPDSA’s 21st annual conference, we acknowledge the grief, loss, and fear the pandemic hasinflicted upon our community, and the world. But Virtual ITP Conference 2021 is also acelebration of hope, marking an emergence from the darkness of this past year as we turntowards the future, celebrating impressive scientific progress and the endurance ofcommunity.

In a year of so much uncertainty, PDSA continues to be the leading resource for ITPpatients around the world. We put our expertise, resources, and passion to work in newand innovative ways to address the unique concerns of the ITP community during theseconfusing and anxiety-inducing times, providing up-to-date information and resourcesabout COVID-19 on our website, adapting our local support group meetings to a virtualsetting, and ensuring the ITP community stayed connected. The availability of COVID-19vaccines brought a renewed sense of hope and promise, but new concerns from the ITPcommunity arose as cases of thrombocytopenia following COVID-19 vaccination beganappearing in the news. The PDSA office received a flood of calls and emails fromconcerned patients and caregivers, and our staff jumped into action to support, educate,and meet the evolving needs of the ITP community. We hosted townhalls with virologistsand immunologists to share the latest COVID-19 and ITP updates, and worked with ourMedical Advisors – leaders in the field and at the forefront of COVID-19 and ITP research –to provide you with accurate, up-to-date information as it became available.

Welcome to Virtual ITP Conference 2021!

We have faced a global pandemic, lockdowns and quarantines, vaccine opportunities andhesitancy, and the triumphs and trials that accompany living with ITP during a publichealth crisis. It has been our busiest year to date, but the purpose and mission of PDSA’swork has remained constant: serving you, the ITP community. We are stronger together.

Virtual ITP Conference 2021

PlateletDisorderSupportAssociation

STRONGER TOGETHER July 30 - August 1

Disease InformationPDSA ProgramsPDSA Research Program & ITP Natural History Study RegistryPump It Up for Platelets!

PDSA Resource Center - Your hub for everything ITP:

Lobby: Navigate the venue with ease through this fully interactive passageway to the Conference

Agenda: The complete conference programBallroom: Attend one of today's sessions or

watch sessions on-demand

Exhibit Hall: Connect with industry; chat,collect materials and share experiences

Lounge: Join the community in one ofour interest-specific lounges

Help Desk: We are available toanswer your questions

Shop: Extraordinary awareness items,educational materials, & medical ID bracelets

PDSAFind your way around Virtual ITP Conference 2021:

GET STARTED: Login at the top-right corner of theplatform! Your login information was emailed toyou prior to the start of the Conference.

AGENDAFRIDAY, JULY 30

4:00 - 7:00 PM EDT Virtual Conference OrientationLearn how to navigate our interactive and user-friendly platform to maximize yourconference experience.

10:00 - 11:00 AM EDT Conference Platform OpensExhibit Hall, Lounge, Live Chat, Help Desk, and Resource Center go live.

12:15 - 12:30PM EDT Break, Exhibit Hall, Lounge

3:15 - 3:30 PM EDT Break, Exhibit Hall, Lounge

1:30 - 1:45 PM EDT Break, Exhibit Hall, Lounge

1:45 - 3:15 PM EDT Current ITP TreatmentsDonald Arnold, MDCM, MSc, FRCP(C); Shruti Chaturvedi,MD; Nichola Cooper, MD; Terry Gernsheimer, MD

SATURDAY, JULY 31

11:00 AM - 12:15 PM EDT ITP Symptoms and CausesTerry Gernsheimer, MD; Michele Lambert, MD, MSTR;Howard Liebman, MD; John Semple, PhD

3:30 - 4:15 PM EDT Empowering patient discussions with physicians throughout theITP journeySponsored by Amgen | A chat between Megan and Ally, an ITP patient advocate,about ways to elevate the role of patients during their discussions with physiciansespecially when it comes to second line therapy selection.

12:30 - 1:30PM EDT Q&A Breakout Sessions

Women & Girls with Bleeding DisordersTerry Gernsheimer, MD; Michele Lambert, MD, MSTR

For Canadians OnlyRobert Klaassen, MD, FRCP(C); John Semple, PhD

The Senior Years: Managing Your ITPCraig Kessler, MD

Teen Talk (for teens only)Michael Tarantino, MD

PDSA

SUNDAY, AUGUST 1

10:00 - 12:15 PM EDT Conference Platform Opens

12:00 - 12:15 PM EDT Break, Exhibit Hall, Lounge

3:00 - 3:15 PM EDT Break, Exhibit Hall, Lounge

1:45 - 2:00 PM EDT Break, Exhibit Hall, Lounge

3:15 - 4:15 PM EDT New Targets for Immune Therapy for ITPDavid Kuter, MD, DPhil

12:15 - 1:45 PM EDT Viruses & Vaccines: What we have learned about COVID-19 and ITPJames Bussel, MD; Annemarie Fogerty, MD; David Kuter, MD, DPhil;Howard Liebman, MD; Marina Beltrami Moreira, MD

2:00 - 3:00 PM EDT Q&A Breakout SessionsITP in Adults

James Bussel, MD; Nichola Cooper, MD; Terry Gernsheimer, MD;David Kuter, MD, DPhil; Howard Liebman, MD; John Semple, PhD

ITP in ChildrenMichele Lambert, MD, MSTR

ITP in Teens for ParentsMichael Tarantino, MD

PRE-RECORDED SESSIONSCommunicating with Your Doctor

Michael Tarantino, MD

PDSA would like to thank everyone who helped make this conference a success. We may nothave been together in person, but the strength of the ITP community continues to shine

through any and all circumstances.

IMPORTANT: Please refrain from sharing personal medical information or details about your personal condition withindustry representatives during Virtual ITP Conference 2021.

11:00 AM - 12:00 PM EDT Support Group Facilitators' WorkshopJody Shy, PDSA Director of Programs and Events;Facilitator Panel

4:15 - 5:00 PM EDT ITP Patient Success Stories and Closing RemarksCaroline Kruse, PDSA President & CEO; Patient Panel

PDSA

Results from the COVID-19 & ITP Survey

338 Respondents. Survey launched February 13, 2021.

Data presented collected through June 4, 2021.

COVID-19 & ITP SURVEY

n=number of people whoresponded to the survey

question

• 98% reported ITP as their primary rare disease • 13% reported having at least one other autoimmune/immune disorder• 35% were in remission at the time they took the survey• 9% reported their platelet count changed following other non-COVID vaccinations

Most Selected Platelet Count Range

Development of ITP

Diagnosed after INFECTION (12%) Diagnosed after VACCINATION (3%) Diagnosed before BOTH (85%)

COVID-19 & ITP

Gender (n=336) and Age (n=332)

Infection Exposure(n=40)

Vaccine Received(n=267)

Vaccine Side Effects(n=24)

• Female respondents (78%)

• Respondents aged < 65 years (83%)

• No reported hospitalizations or deaths• Platelet count decrease (33%)• Platelet count increase (18%)• Platelet count unchanged (46%)• Average time to return to baseline was 2-4 weeks

• Moderna (38%)• Pfizer (45%)• AstraZeneca or J&J (14%) • Platelet count decrease (32%)• Platelet count increase (15%)• Platelet count unchanged (53%)• Average time to return to

baseline was 2-4 weeks• Two blood clots reported

Most frequently reported symptoms:• Headache• Chills/fever• Fatigue• Large drop in platelet

count (-100K) reported by 5 participants

Post-Infection (n=40)

Post-Vaccination Dose 2 (n=137)

Post-Vaccination Dose 1 (n=267)Platelet count increase

10,000-50,000Platelet count decrease

10,000-50,000

research@pdsa.org Platelet Disorder Support Association

Platelet count increase 10,000-50,000

Platelet count decrease 10,000-50,000

Platelet count increase10,000-50,000

Platelet count decrease10,000-50,000

SPEAKERS

Donald Arnold, MDCM, MSc, FRCP(C)

Dr. Donald M. Arnold is a Professor in the Department of Medicine at McMasterUniversity, and Director of the McMaster Centre for Transfusion Research. Dr.Arnold’s focus of research is on platelet disorders including immunethrombocytopenia (ITP). Other research areas include blood transfusion practices,optimal utilization of blood products, blood safety and novel treatments. Dr. Arnoldis the lead investigator for several multicentre clinical trials in Hemostasis andTransfusion Medicine and has built a translational research program in blooddisorders that includes a basic serology laboratory. Dr. Arnold has received fundingfrom the Canadian Institutes of Health Research and Canadian Blood Services forhis research. Dr. Arnold also serves on the PDSA Board of Medical Advisors.

Shruti Chaturvedi, MD, MBBS, MS

Dr. Shruti Chaturvedi is an Assistant Professor of Medicine in the Division ofHematology at Johns Hopkins University School of Medicine. She received hermedical degree from the University of Delhi in India and went on to complete aresidency in Internal Medicine from the Cleveland Clinic and a fellowship inHematology and Oncology from Vanderbilt University. During her fellowship, shealso completed a Master of Science in Clinical Investigation, with a focus on geneticmodifiers of hematologic disorders. Her clinical practice is focused on immunemediated benign hematologic disorders including ITP, TTP, and theantiphospholipid syndrome. Her research is focused on thromboticmicroangiopathy, particularly long-term complications, as well as the role ofcomplement in other hematologic disorders. She has been supported by grantsfrom the American Society of Hematology, the Hemostasis and ThrombosisResearch Society, and National Institutes of Health.

James Bussel, MD

Dr. James Bussel is a Professor of Pediatrics, Medicine, and Obstetrics at the WeillMedical College of Cornell University in New York City. His training was initiated atYale, continued at Columbia College of Physicians and Surgeons, then he completeda Pediatric Residency at Cincinnati Children’s Hospital, and a Fellowship in PediatricHematology/Oncology at the combined Cornell/Memorial Sloan Kettering program.The great majority of Dr. Bussel’s publications are centered around diagnosis andespecially management of patients with ITP, including children with ITP, adults withITP, pregnant women with ITP, HIV-infected patients with thrombocytopenia, andfetuses affected by autoimmune and alloimmune thrombocytopenia. He hasworked with IVIg, IV anti-D, rituximab, and most recently the thrombopoietic agents.In 2012, he received the King Faisal Prize for Medicine, known as the Arab NobelPrize. Dr. Bussel also serves on the PDSA Board of Medical Advisors.

PDSA

Nichola Cooper, MD

Dr. Nichola Cooper is a Senior Lecturer and Honorary Consultant Haematologist atHammersmith Hospital, Imperial College, London, UK. She completed herundergraduate degrees at Cambridge University and Barts and the London HospitalMedical College, University of London, UK. During her haematology training, Dr.Cooper undertook a research fellowship at Cornell Medical School, New YorkPresbyterian Hospital, USA with Jim Bussel, investigating the clinical and laboratoryimpact of treatments such as rituximab and anti-D immunoglobulin in patients withITP. She also studied at Great Ormond Street Hospital and the Royal Free Hospital,London, where she gained further experience in both paediatric and adultimmunodeficiency disorders. Dr. Cooper runs a clinical and laboratory researchprogramme investigating the causes of haematological autoimmunity. She hasauthored many papers published in international, peer-reviewed journals includingNature Immunology, Blood and the British Journal of Haematology. Dr. Cooper alsoserves on the PDSA Board of Medical Advisors.

Terry Gernsheimer, MD

Dr. Terry Gernsheimer is a Professor of Medicine at the University of WashingtonSchool of Medicine and the Medical Director of Transfusion at the Seattle CancerCare Alliance. Dr. Gernsheimer’s research focuses on the pathophysiology andtreatment of immune platelet disorders and pathologic immune responsesassociated with transfusion. She has clinical research interest in transfusionmanagement of the hematopoietic stem cell transplant patient and surgicalbleeding in patients undergoing solid organ transplant and cardiovascularprocedures. She has made significant contributions toward understanding thepathophysiology and management of ITP. Dr. Gernsheimer also serves on the PDSABoard of Medical Advisors.

Annemarie Fogerty, MD

Dr. Annemarie Fogerty is a Hematology Specialist in Boston, MA with over 18 yearsof experience. She graduated from New York University School of Medicine in 2003,then went on to internal medicine residency at Massachusetts General Hospital. Shecompleted her fellowship training at the Dana Farber Cancer Institute. She currentlyserves as the Clinical Director for Hematology and Director of ReproductiveHematology at both Massachusetts General Hospital and Newton-WellesleyHospital. Her particular areas of clinical expertise and research focus onthrombocytopenia and thrombosis in the pregnant patient.

PDSA

PDSACraig Kessler, MD

Dr. Craig Kessler is a Professor of Medicine and Pathology and Section Chief ofHematology at Georgetown University. He is also Director of the CoagulationLaboratory at Georgetown. A graduate of Tulane School of Medicine, Dr. Kesslerreceived his specialty training in hematology and oncology at The Johns HopkinsHospital. An international expert in disorders of coagulation, Dr. Kessler has aparticular interest in hemophilia and also has expertise in the treatment ofhematologic malignancies. Dr. Kessler serves on the PDSA Board of MedicalAdvisors.

Robert Klaassen, MD, FRCP(C)

Dr. Robert Klaassen is a Pediatric Hematologist/Oncologist at the Children’s Hospitalof Eastern Ontario, Professor at the Department of Pediatrics, University of Ottawaand Clinical Investigator at the CHEO Research Institute. He is the Hemophiliadirector for the Eastern Ontario region and is the past President of the Associationof Hemophilia Directors of Canada. His clinical focus is on the care of patients withnon-malignant hematologic disorders and in particular bleeding disorders. Hisresearch activities specialize in quality of life and he is one of the owner/inventors ofthe Kids ITP tools (KIT), which is a quality of life tool specific developed for childrenwith ITP.

David Kuter, MD, DPhil

Dr. David Kuter is a Professor of Medicine at Harvard Medical School and Chief ofHematology, Massachusetts General Hospital, Boston, Massachusetts. He earned aresearch doctorate (DPhil) at Magdalen College of Oxford University and a medicaldegree at Harvard Medical School. Dr. Kuter sits on numerous national andinternational ITP committees and is board-certified in Internal Medicine,Hematology, and Medical Oncology. He has dedicated years of effort to researchingcoagulopathies, anticoagulation, and platelet disorders. In recent years, Dr. Kuterhas conducted groundbreaking research into the development of effectivethrombopoietic agents. Dr. Kuter also serves on the PDSA Board of MedicalAdvisors.

Michele Lambert, MD, MSTR

Dr. Lambert is an Associate Professor of Pediatrics at the Perelman School of Medicineat the University of Pennsylvania (UPENN) and Children’s Hospital of Philadelphia(CHOP) and Medical Director of the Special Coagulation Laboratory at CHOP. Shegraduated from UMDNJ-New Jersey Medical School (now Rutgers) and completed herpediatric residency at St. Christopher’s Hospital for Children followed by a year as ChiefResident. She then moved to the Children’s Hospital of Philadelphia where shecompleted her fellowship in pediatric hematology/oncology. She received her Mastersin Translational Medicine in 2001 from UPENN. Her research efforts have focused onunderstanding the control of platelet production by megakaryocytes (the cells thatmake platelets) and the ways in which genetics influence platelet function and numberin various clinical scenarios including ITP and inherited platelet disorders as well as thecomplex interplay of the immune system and genetics on the development of systemicautoimmune disease. Dr. Lambert also serves on the PDSA Board of Medical Advisors.

Howard Liebman, MD

Dr. Howard Liebman is Professor of Medicine and Pathology at the University ofSouthern California (USC) Keck School of Medicine, Los Angeles, CA. He serves as MedicalDirector of the Special Hemostasis Laboratory at the USC Norris Comprehensive CancerCenter and is Director of the fellowship program in hematology. Dr. Liebman receivedhis medical degree from USC and completed his postgraduate training, including aresidency in internal medicine and fellowships in medical oncology and hematology, atLos Angeles County – University of Southern California Medical Center. Dr. Liebmancompleted a research fellowship at Tufts University – New England Medical Center,Boston, MA, and held faculty positions at Tufts University and Boston University beforereturning to USC. Dr. Liebman’s research interests include clinical management andcharacterization of haemostatic and thrombotic disorders, management of autoimmuneblood disorders, and clinical therapy of HIV and AIDS. He has authored or co-authored85 peer-reviewed publications and 26 reviews and chapters. Dr. Liebman serves on thePDSA Board of Medical Advisors.

PDSA

Marina Beltrami Moreira, MD

Dr. Marina Beltrami attained her MD in Brazil, where she also pursued graduatestudies in epidemiology and clinical research in Cardiovascular Medicine. In 2012she was awarded the J.P. Lemann Cardiovascular Research Fellowship and studiedinflammation and vascular biology at the Brigham and Women’s Hospital/HarvardMedical School. She resumed her clinical training in Internal Medicine in 2016 atNorwalk Hospital, CT, where she served as Chief Resident in 2019-2020. Her clinicalinterest shifted to hematology, and she is currently a clinical fellow in Hematologyand Medical Oncology at New York-Presbyterian/Weill Cornell Medicine.

Michael Tarantino, MD

Dr. Michael Tarantino is a Professor of Pediatrics and Medicine at the University of IllinoisCollege of Medicine – Peoria and Medical Director of The Bleeding & Clotting DisordersInstitute. He received a doctoral degree in medicine from the University of WisconsinSchool of Medicine in 1987. He completed an internship and residency at the Universityof Arizona Health Sciences Center and a Fellowship in Pediatric Hematology/Oncology atthe University of Wisconsin School of Medicine. Dr. Tarantino first became interested inITP during his residency in 1988. Since that time, he has designed and/or participated innumerous clinical investigations related to ITP and other platelet disorders. He hasauthored numerous publications relevant to the diagnosis and management of ITP,especially as it occurs in children. He is also active in hemophilia and other bleedingdisorders research and founded The Bleeding and Clotting Disorders Institute in 2010.Dr. Tarantino also serves on the PDSA Board of Medical Advisors.

John Semple, PhD

Dr. John Semple received his PhD in Immunology from Queen’s University in 1986 andtrained as a Post-Doctoral Fellow in the Banting and Best Department of MedicalResearch of the C.H. Best Institute, University of Toronto, from 1986-1990. He joined St.Michael’s Hospital in 1990 and was a Senior Staff Scientist and Head of the TorontoPlatelet Immunobiology Group at the Keenan Research Centre for Biomedical Sciences.He was also a Professor in the Departments of Pharmacology, Medicine and LaboratoryMedicine and Pathobiology at the University of Toronto, and an Adjunct Scientist withCanadian Blood Services. He joined Lund University in 2016 as a Professor ofTransfusion medicine of St. Michael’s Hospital. Dr. Semple has published over 120papers on platelet immunology. His research activities include anti-platelet T cellresponses in patients with acute and chronic ITP, the analysis of how platelet antigensare recognized by the immune system, and how platelets may act as immune-like cellsthat are responsible for initiating and perpetuating their own autoimmune demise. Dr.Semple serves on the PDSA Board of Medical Advisors.

PDSA

COME JOIN OUR CHAT

WITH ALLY, OUR PATIENT ADVOCATE,

AS WE DISCUSS EMPOWERING PATIENT DISCUSSIONS WITH PHYSICIANS

THROUGHOUT YOUR TREATMENT JOURNEY:

Saturday, July 31st 3:30pm EDT

Visit the Amgen booth, where you can access resources to better understand Nplate®-related patient support programs,

namely financial support options.

Go to Nplate.com for more information.

Restricted DonationsRestricted donations are also greatly appreciated and can have great impact on specificprograms such as our PDSA Research Program and our College Scholarship Program.

WAYS TO GIVEI n a d d i t i o n t o m e m b e r s h i p a n d f u n d r a i s e r s ,t h e r e a r e m a n y w a y s t h a t y o u c a n s u p p o r t

o u r i m p o r t a n t w o r k . P D S A i s a 5 0 1 ( c ) 3n o n p r o f i t o r g a n i z a t i o n a n d y o u r c h a r i t a b l e

s u p p o r t i s t a x - d e d u c t i b l e .

PLATELET DISORDER SUPPORT ASSOCIATION | 440-746-9003 | pdsa@pdsa.org | www.PDSA.org

Unrestricted Charitable DonationsCharitable donations help advance PDSA's efforts in education, advocacy, research, andsupport. Unrestricted donations offer us flexibility in putting your gift to use where it isneeded most!

Gifts of SecuritiesPDSA also welcomes asset-based donations such as gifts of stock, securities, and other assets.

Tribute GiftsIn times of great joy or sorrow, people often make a gift to PDSA in honor or in memory ofloved ones. Tribute gifts can be unrestricted or earmarked for a restricted program asidentified above.

Matching GiftsDouble Your Donation to PDSA at no cost to you! Does your employer match charitable gifts?If so, you may be able to double your donation to PDSA through a matching gift program!Check with your Human Resources Department to learn more.

Workplace & Outside Giving ProgramsCharitable gifts can be made directly or indirectly to PDSA through the following workplaceand outside giving programs:

at thowe@pdsa.org or 440-746-9003

Support PDSA today at pdsa.org/giveQuestions? Contact Teri Howe, Director of Development and Communications,

PDSA Legacy SocietyHave you considered including a gift to PDSA in your estate plan? The Legacy Societyrecognizes those who have named the Platelet Disorder Support Association through a bequestin their will, or created other types of planned/legacy gifts - including a beneficiary designation,such as retirement assets or a life insurance policy - in support of our important work.

PLATELET DISORDER SUPPORT ASSOCIATION | 440-746-9003 | pdsa@pdsa.org | www.PDSA.org

Join the distinguished society of supporters whose gracious giftsstrengthen our financial independence, sustain our l ifesavingwork, and shape the future for ITP.

Cathy & Raul AldamaAnonymousCindy & J. Philip AyliffGerald BarnesGigi BarryMary & James BenvenutoAmita & Ranjive BhallaKristin Henrikson & Jon BrandtBrendan CameronMadison CarrollMichele & Darren ChocholekIsaac ClerenciaKristy ColemanCharlotte Cunningham-Rundles, MD

& James Bussel, MDJennifer & Luigi DiRaimoKim & Jim EverettMitchell FaccioVeronica & Desie FernandezJan & Steve GardnerTerry Gernsheimer, MDJen & Benjamin GrimesKim & Rodney HallStephanie HalperinMira & Jim HausserPatricia & Bennett HenriksonNoelle & Mat HeymanArlene & David HorowitzMadeline & John HromyakSherill HudsonKaren & David ImigMary & James IngmireJerry JonesChris JordanJoan & Rich JordanEmily & Kris KileLouise Kittel MasonJennifer & Bob KruegerCaroline & Ken Kruse

Irene & David Kuter, MD, DPhilJordan & John LawsonLauren LayDiane & Arthur LevinDavid LihaniJenn & Andy Lindal

/For the Love of GracieMarcy LuffmanVictor LuisMary Lou LyonsKarin MagnusonJanet & William McAllisterKatherine McClearyKaren Rosenbaum

& Ben McClintonThe McGuirl FamilyIrma & Daniel MilesStephanie & Mike MoranLouann MurtaghTracey ParkerSusan & Dale PaynterJonathan PeischlJeanne & Dan PinnellPenny PiperMeredith PrescottPatricia & John ProescholdtBarbara & Peter Pruitt, Jr.Shirley & Peter Pruitt, Sr.

Circle of Hopemembers donate or

raise $1,000 or morewithin a calendar yearand serve as PDSA'sphilanthropic leaders.

Patricia PulleyAshley & Greg RandolphVirginia RennieToni RobergeSteven RodgersDavid ShermanJody & Jon ShyJulie & Michael SpiekerJaneen & Robert TheobaldDeborah Rabinowitz, MD

& Justin TocciKristen & Steve TomczakLois UmhoeferTheresa & Tony WaxlaxElizabeth & Robert WelchEmmerson WinnieJoseph WinterBarbara & Stanley WooleverCheri & Derek ZimmermanJoyce & Dale Zimmerman

Visit: pdsa.org/circle-of-hope

Visit our virtual booth at the 2021 PDSA ITP Conference to learn more and download the resources we offer.

YOU SHOULDN’T HAVE TO BUILDYOUR LIFE AROUND YOUR TREATMENT

Come see how you can make the most of your ITP treatment journey.

Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936-1080 © 2021 Novartis Printed in USA 7/21 134507

Join us at theFacilitators' WorkshopSunday morning at

11:00 AM EDT!

Over 50 local supportgroups across the U.S.,Canada, & New Zealand

450+ individualsattended a local supportgroup meeting in 2020

12,350+ members15 interest-specificdiscussion threads

300+ participatingfamilies

Q&A with a pediatrichematologist

PDSA.ORG discussion FORUM

Offers 24/7 support to patients and caregivers.

local SUPPORT GROUPS

With all local meetings currently being held virtually, it's easier than ever to get connected!

PArents of kids with itp teleconference

Children with ITP get a chance to meet each other and talk,plus time for parent-to-parent support and discussion.

PDSA’s ITP Patient ConnectPatient & Caregiver Support Network

YOU ARE NOT ALONE.

Find strength, support, andcommunity with ITP Patient

Connect. Visit pdsa.org/support-groups

for more information.

ITP Symptoms and CausesTerry Gernsheimer, MD; Michele Lambert, MD, MSTR;Howard Liebman, MD; John Semple, PhD

PDSA

Q&A: Breakout SessionsWomen & Girls with Bleeding Disorders

Terry Gernsheimer, MD;Michele Lambert, MD, MSTR

The Senior Years: Managing Your ITPCraig Kessler, MD

For Canadians OnlyRobert Klaassen, MD,FRCP(C); John Semple, PhD

Teen TalkMichael Tarantino, MD

PDSA

Current ITP TreatmentsDonald Arnold, MDCM, MSc, FRCP(C); Shruti Chaturvedi, MD;Nichola Cooper, MD; Terry Gernsheimer, MD

PDSA

Viruses & Vaccines: What we have learned about COVID-19 and ITPJames Bussel, MD; Annemarie Fogerty, MD; David Kuter, MD, DPhil;Howard Liebman, MD; Marina Beltrami Moreira, MD

PDSA

Q&A: Breakout SessionsITP in Adults

James Bussel, MD; Nichola Cooper, MD; Terry Gernsheimer, MD; DavidKuter, MD, DPhil; Howard Liebman, MD; John Semple, PhD

ITP in ChildrenMichele Lambert, MD, MSTR

ITP in Teens For ParentsMichael Tarantino, MD

PDSA

New Targets for Immune Therapy for ITPDavid Kuter, MD, DPhil

PDSA

PRE-RECORDED:

Michael Tarantino, MDCommunicating With Your Doctor

PDSA

Enjoy 20% off at the Platelet Store,

starting Friday, July 30 at 6 PM throughSunday, August 1 at 6 PM!

Special ConferenceDiscount at the

Platelet Store!

Virtual ITP Conference 2021

PlateletDisorderSupportAssociation

STRONGER TOGETHER July 30 - August 1

SPECIAL THANKS

We are thankful to the many people and corporations whohelped make our virtual conference a success.

PDSA | 8751 Brecksville Rd. | Suite 150 | Cleveland, OH | 44141440-746-9003 | pdsa@pdsa.org | www.pdsa.org

Volunteers andAmbassadors:

Julie AgiusHaley AgiusKarin de BoerTheo de WispaelareTammy FassettMelissa HilsabeckLindsey Hoefft

Sebastian HoefftKristin HuntBarbara JacobsJim JacobsMervyn MorganSharon MorganDale Paynter

Dawn PhillipsJohn PhillipsBarbara PruittSara ReesorJana ReschLogan ReschTrish Santaromana

Speakers: Donald M. Arnold, MDCM, MSc, FRCP(C)James Bussel, MDShruti Chaturvedi, MBBS, MSNichola Cooper, MDTerry Gernsheimer, MDAnnemarie Fogerty, MD

Andra James, MD, MPHDavid Kuter, MD, DPhilMichele Lambert, MD, MSTREun-Ju Lee, MDJohn Semple, PhDMichael Tarantino, MD

Gold Sponsors: Novartis, SobiPlatinum Sponsor: Amgen

Silver Sponsors: Argenx, Rigel, UCB

Corporate Silver Member: Sanofi

Canadian Educational Session and Lounge

Supporting Member: Pfizer

Bronze Sponsor: Novartis CanadaGold Sponsor: Amgen Canada

In Appreciation:

ITP ConferenceWelcome Video:

Marcia FreedBarbara JacobsRia MarshClara Wildeman

EDUCATION

ADVOCACY

RESEARCH

SUPPORT

ITP Poke-R Club for Kids: free clinical support program for PDSAMembers in the U.S. & Canada designed to alleviate the anxiety

of children coping with chronic ITP

Empowering the ITP community since 1998 withinnovative and patient-centered programming.

The Platelet DisorderSupport Association

We are

ITP Insights: Critical Topics in Immune Thrombocytopenia:NEW patient education webinar series connecting ITP patients,

caregivers, and their families with clinical experts

Health Care Professional (HCP) Resources: detailed resources onITP care to keep physicians and hematologists up to date on thelatest ITP news, disease guidelines, and treatment developments

PDSA College Scholarship Program: Provides financialassistance to senior high school students, college students or

adults interested in continuing education with ITP

Learn more at PDSA.org

FOR OUR SESSION ON EMPOWERING PATIENT DISCUSSIONS WITH PHYSICIANS

THROUGHOUT YOUR TREATMENT JOURNEY:

COME JOIN US

Visit the Amgen booth, where you can access resources to better understand Nplate®-related patient support programs,

namely financial support options.

Go to Nplate.com for more information.

Nplate® is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved. USA-531-80772 06/21

Saturday, July 31st 3:30pm EDT